Preventing resistance to T‑cell therapies in multiple myeloma
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple Myeloma
The team is developing ways to stop CAR‑T and bispecific antibody treatments from losing effectiveness in people with relapsed or refractory multiple myeloma.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Arizona NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project ID | NIH-11176763 on NIH RePORTER |
What this research studies
This project looks at why CAR‑T and bispecific antibody therapies often stop working by studying myeloma cells and the bone marrow environment. Researchers will analyze patient bone marrow samples and use laboratory models to study two resistance mechanisms: myeloma cells entering a therapy‑induced dormant state and bone marrow cancer‑associated fibroblasts that suppress T‑cell activity. They will test strategies in the lab to reverse dormancy or block the fibroblast‑driven suppression, with the aim of finding treatments that keep T‑cell therapies working longer.
Who could benefit from this research
Good fit: Ideal candidates are people with relapsed or refractory multiple myeloma, especially those who have received or are planning to receive CAR‑T or bispecific antibody therapy, or who can donate bone marrow samples.
Not a fit: People without multiple myeloma or those not eligible for T‑cell directed therapies would not be expected to benefit directly.
Why it matters
Potential benefit: If successful, this work could lead to treatments that prolong remissions and lower the chance of relapse after CAR‑T or bispecific antibody therapy.
How similar studies have performed: CAR‑T and bispecific antibody therapies have produced strong responses in multiple myeloma but relapses remain common, and earlier studies have suggested dormancy and microenvironment suppression as resistance factors, so this work builds on promising but still emerging evidence.
Where this research is happening
Scottsdale, United States
- Mayo Clinic Arizona — Scottsdale, United States (Active)
Researchers
- Principal investigator: Lin, Yi — Mayo Clinic Arizona
- Study coordinator: Lin, Yi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.